457 related articles for article (PubMed ID: 24420551)
1. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
[TBL] [Abstract][Full Text] [Related]
3. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats.
Schupp N; Kolkhof P; Queisser N; Gärtner S; Schmid U; Kretschmer A; Hartmann E; Oli RG; Schäfer S; Stopper H
FASEB J; 2011 Mar; 25(3):968-78. PubMed ID: 21135038
[TBL] [Abstract][Full Text] [Related]
5. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Hypertension; 2003 Mar; 41(3):493-8. PubMed ID: 12623949
[TBL] [Abstract][Full Text] [Related]
6. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
7. Grape seed proanthocyanidins prevent DOCA-salt hypertension-induced renal injury and its mechanisms in rats.
Lan CZ; Ding L; Su YL; Guo K; Wang L; Kan HW; Ou YR; Gao S
Food Funct; 2015 Jul; 6(7):2179-86. PubMed ID: 26011796
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
9. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
10. Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway.
Wu C; Chen Z; Zhang L; Zhu Y; Deng M; Huang C; Liu Y; Zhu Q; Wang L
Hypertens Res; 2021 Feb; 44(2):168-178. PubMed ID: 32908237
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats.
Iwazu Y; Muto S; Hirahara I; Fujisawa G; Takeda S; Kusano E
J Hypertens; 2011 Dec; 29(12):2440-53. PubMed ID: 22045122
[TBL] [Abstract][Full Text] [Related]
12. Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats.
Van den Berg DT; de Kloet ER; de Jong W
Am J Physiol; 1994 Dec; 267(6 Pt 1):E927-33. PubMed ID: 7810636
[TBL] [Abstract][Full Text] [Related]
13. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
Ndisang JF; Jadhav A
J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension.
Krebs CF; Lange S; Niemann G; Rosendahl A; Lehners A; Meyer-Schwesinger C; Stahl RA; Benndorf RA; Velden J; Paust HJ; Panzer U; Ehmke H; Wenzel UO
Hypertension; 2014 Mar; 63(3):565-71. PubMed ID: 24366079
[TBL] [Abstract][Full Text] [Related]
15. Resting Afferent Renal Nerve Discharge and Renal Inflammation: Elucidating the Role of Afferent and Efferent Renal Nerves in Deoxycorticosterone Acetate Salt Hypertension.
Banek CT; Knuepfer MM; Foss JD; Fiege JK; Asirvatham-Jeyaraj N; Van Helden D; Shimizu Y; Osborn JW
Hypertension; 2016 Dec; 68(6):1415-1423. PubMed ID: 27698066
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
[TBL] [Abstract][Full Text] [Related]
17. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
Carneiro FS; Nunes KP; Giachini FR; Lima VV; Carneiro ZN; Nogueira EF; Leite R; Ergul A; Rainey WE; Clinton Webb R; Tostes RC
J Sex Med; 2008 Dec; 5(12):2793-807. PubMed ID: 18823320
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis.
Iwazu Y; Muto S; Fujisawa G; Nakazawa E; Okada K; Ishibashi S; Kusano E
Hypertension; 2008 Mar; 51(3):749-54. PubMed ID: 18250361
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis.
Young M; Funder J
Endocrinology; 2003 Sep; 144(9):3848-51. PubMed ID: 12933657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
